Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 10 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 12029777

    Serine proteinase inhibitors: Serp-1 and Serp-1 RCL-derived peptides effect on microbiome composition and uses thereof

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  2. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  3. US 12024509

    Therapeutic compounds as inhibitors of the orexin-1 receptor

    C4X Discovery Limited · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  4. US 12018259

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  5. US 12018027

    Macrocyclic derivatives acting as XIa factor inhibitor

    China Resources Biopharmaceutical Company Limited · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  6. US 12018017

    Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  7. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  8. US 12016835

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  9. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    NURIX THERAPEUTICS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  10. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  11. US 12012467

    Small molecule DCN1 inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  12. US 12006355

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    The Regents of the University of California · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  13. US 12005127

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  14. US 11999747

    Furoquinolinediones as inhibitors of TDP2

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  15. US 11999753

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  16. AU 2022390453

    NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS

    ANGELINI PHARMA S P A [IT] · Granted May 30, 2024 · Expires May 25, 2044

    granted
  17. US 11992480

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  18. US 11993603

    Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted May 28, 2024 · Expires May 23, 2044

    granted
  19. US 11993594

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  20. US 11980633

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 14, 2024 · Expires May 9, 2044

    granted
  21. US 11969435

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  22. US 11964989

    KRas G12D inhibitors

    Mirati Therapeutics, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  23. US 11963958

    RET inhibitor for use in treating cancer having a RET alteration

    Rigel Pharmaceuticals, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  24. US 11963959

    Inhibitors for coronavirus

    The Government of the United States, as represented by the Secretary of the Army · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted